A multiple patient expanded access program for olaparib tablets for the maintenance treatment following response (complete response or partial response) to platinum-based chemotherapy in patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.
18 Years - 120 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Oct 2017 by AstraZeneca
No locations available